280 Participants NeededMy employer runs this trial

Tradipitant for Nausea and Vomiting

Recruiting at 9 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Vanda Pharmaceuticals
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.

Who Is on the Research Team?

VP

Vanda Pharmaceuticals Inc.

Principal Investigator

Vanda Pharmaceuticals Inc.

Are You a Good Fit for This Trial?

Inclusion Criteria

Body Mass Index ≥ 25 and < 40 kg/m^2
I do not have any serious medical conditions or diabetes.

Exclusion Criteria

Exposure to any investigational medication within the past 60 days
History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
I have another condition that causes digestive symptoms.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either tradipitant or placebo BID for approximately 2 weeks

2 weeks
Daily symptom diary entries

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 week

What Are the Treatments Tested in This Trial?

Interventions

  • Tradipitant

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: Tradipitant GroupExperimental Treatment1 Intervention
Group II: Placebo GroupPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vanda Pharmaceuticals

Lead Sponsor

Trials
68
Recruited
19,900+